Randomized trial · people

Tirzepatide: sleep apnea gains beat placebo by week 20 in SURMOUNT-OSA

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, tirzepatide improved pAHI from baseline by Week 4, took until Week 20 to clearly beat placebo, and gains were larger in people who lost more weight.

Kind
Randomized trial
Studied in
People
Published
2025
Journal
Sleep Med

What they tested

The team asked how quickly tirzepatide improved sleep apnea measures and how closely those improvements tracked weight loss.

How the study was done

A post hoc analysis, meaning one planned after the main results, of two 52-week, randomized, double-blind, placebo-controlled Phase 3 studies in adults with obstructive sleep apnea. It used linear regression to look at effects tied to weight loss and effects not tied to it.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In Study 1, readings from a sleep device, the WatchPAT 300, matched results from polysomnography, a full overnight sleep test. On the device, tirzepatide improved the peripheral apnea-hypopnea index (pAHI, a count of breathing pauses and shallow breaths per hour of sleep) compared with baseline as early as Week 4. The gap versus placebo, a dummy treatment, did not become significant until Week 20, both for pAHI and for sleep apnea-specific hypoxic burden (SASHB, how much oxygen levels fall during breathing events). In both studies, larger weight loss went along with larger changes in AHI and SASHB.

What it doesn’t show

This was a post hoc analysis, so it was not the trial's main test. It shows that improvement went along with weight loss, but it could not separate the effect of weight loss from other effects of tirzepatide. The authors say more research is needed on that question.

The paper

Malhotra et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. Sleep Med. 2025.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo